

Product News

Lonza Announces Planned Temporary Shutdown of Niacin Plant in Visp

Basel, Schweiz, 11 April 2013 - Lonza today announced that it will shut down temporarily its' Niacin production plant in Visp, Switzerland. The planned shutdown will occur in May 2013 for a few weeks to perform routine maintenance work.

About Lonza

Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers' needs from research to final product manufacture. It is the global leader in the production and support of chemical and biological active pharmaceutical ingredients. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is also the world leader in microbial control providing innovative, chemistry-based and related solutions to destroy or to selectively inhibit the growth of harmful microorganisms. Its activities encompass the areas of water treatment, personal care, health and hygiene, industrial preservation, materials protection, and wood treatment. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition and agro markets.

Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange and secondary listed on the Singapore Exchange Securities Trading Limited ("SGX-ST"). In 2012, the company had sales of CHF 3.925 billion. Further information can be found at www.lonza.com.

Further Information

Lonza Group Ltd
Life Science Ingredients - Nutrition
Director of Marketing and Sales
Matthias Schaub
Tel +41 61 316 8552
matthias.schaub@lonza.com